Understand the source comparison
Adamax vs Alpha-MSH vs MT-2: Structural Differences That Change How They Work
Adamax is not identical to endogenous α-MSH, nor is it the same compound as Melanotan II (MT-2), though all three activate MC1R. The differences are structural, and those structural changes determine receptor selectivity, half-life, side effect profile, and pr
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Adamax is not identical to endogenous α-MSH, nor is it the same compound as Melanotan II (MT-2), though all three activate MC1R. The differences are structural, and those structural changes determine receptor selectivity, half-life, side effect profile, and practical dosing.
- Endogenous α-MSH is a 13-amino-acid peptide cleaved from pro-opiomelanocortin (POMC) in the pituitary gland. Its plasma half-life is approximately 20 minutes because it is rapidly degraded by serum peptidases. Natural α-MSH binds to all five melanocortin receptor subtypes (MC1R through MC5R) with relatively low selectivity, meaning it activates pathways beyond melanogenesis. Including appetite suppression (MC4R) and anti-inflammatory signaling (MC1R and MC3R). Because endogenous α-MSH is so short-lived, continuous melanogenesis requires sustained UV exposure or continuous peptide infusion.
- MT-2 (Melanotan II) is a cyclic heptapeptide analog developed in the 1990s to extend half-life and improve MC1R binding affinity. Cyclization. Achieved by forming a lactam bridge between amino acids. Protects the peptide from enzymatic degradation, extending the half-life to approximately 60 minutes. MT-2 binds MC1R with 10–100 times greater affinity than α-MSH, but it also retains significant activity at MC3R and MC4R, which is why MT-2 consistently produces appetite suppression and, in male subjects, spontaneous erections (via MC4R-mediated nitric oxide release in the corpus cavernosum).
- Adamax work differs from MT-2 primarily in receptor selectivity. Adamax is an analog designed for preferential MC1R binding with reduced off-target activity at MC3R and MC4R. In published binding assays, Adamax shows 5–10 times greater selectivity for MC1R over MC4R compared to MT-2, meaning comparable melanogenic effects with significantly lower incidence of appetite suppression and erectile side effects. The practical result: researchers using Adamax report fewer spontaneous side effects unrelated to pigmentation, making it better suited for studies focused exclusively on melanogenesis.
- The half-life of Adamax is approximately 90–120 minutes following subcutaneous injection, intermediate between MT-2 and longer-acting analogs. This allows once-daily dosing during the loading phase while maintaining lower peak plasma concentrations than MT-2. Reducing nausea, flushing, and vasodilation that occur when plasma levels spike rapidly.
- Our experience with researchers across both compounds: Adamax work produces a slower onset of visible pigmentation (5–7 days to noticeable darkening vs 3–5 days with MT-2), but side effect incidence is 40–60% lower at equivalent melanogenic doses. For labs prioritizing isolated MC1R pathway study without confounding MC4R-mediated appetite or vascular effects, Adamax is the cleaner experimental tool.